PURE Bioscience to Report Second Quarter Fiscal 2012 Results on March 16
Conference Call to Begin at 4:30 p.m. Eastern
SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience, Inc. (NASDAQ: PURE) today announced that it will report results for the second quarter of fiscal year 2012 after market close on Friday, March 16, 2012.
Michael L. Krall, President and CEO, will host a conference call on Friday, March 16, 2012 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to review and discuss second quarter financial results, and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing 877-407-8033 or (International) 201-689-8033 a few minutes before the call start time.
The webcast will be available for replay through March 16, 2013. A telephone replay of the conference call will be accessible until midnight May 16, 2012 by dialing 877-660-6853 or (International) 201-612-7415, and entering the Account #: 286 and the Conference ID #: 390528.
About PURE Bioscience (PURE)
PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
PURE Investor Contact:
Don Markley, Senior Vice President
PURE Media Contact:
Source: PURE Bioscience, Inc.Copyright Business Wire 2012